SEC Form 4 · accession 0001171843-18-001619
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Hayden
Director
Period of report
Feb 22, 2018
Accepted (ET)
Mar 1, 2018 · 6:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Feb 22, 2018 | G | 29,580 | $0.00 | D | 131,607 | D | |
| Common Shares | Feb 22, 2018 | G | 21,180 | $0.00 | A | 97,066 | I | By Spouse |
| Common SharesF2 | holding | — | — | — | 30,348 | I | By Genworks Inc. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F18,400 of these shares were gifted to family members that do not share the reporting person's household.
- F2Michael Hayden is the president and principal beneficial shareholder of Genworks Inc.